Viatris Inc. Share Price & Technical Analysis

VTRS · $16.65 (+1.15%)

Healthcare / Drug Manufacturers - Specialty & Generic

AI Score 50 · Weak

$16.65

+1.15%

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and b

Price chart

Seasonality

May has 3 positive and 2 negative years (last 5 years shown)

11% return in May, -2% avg return in past 3 year May month.

30% return in 2026, 8% avg return in past 3 years.

Swipe sideways to see all months →

JanFebMarAprMayJunJulAugSepOctNovDecYr
265%14%-9%10%11%30%
25-9%-18%-6%-3%5%2%-3%22%-6%5%4%17%9%
249%6%-4%-3%-9%-1%13%0%-3%0%12%-5%16%
239%-6%-16%-4%-2%10%6%3%-8%-14%3%19%0%
2210%-27%-3%-6%18%-15%-7%-1%-11%17%8%1%-14%

Monthly return % by calendar month · historical pattern, not a forecast

AI snapshotScore 50/100

Weak · Strong · Strong

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Full AI Q&A, portfolio tracking, and live alerts in the app.

Key metrics

Market cap

$19.77B

P/E ratio

52W high

$17.53

52W low

$8.32

Volume

73,62,139

Beta

0.87

Related stocks in Healthcare

Frequently asked questions

What is Viatris Inc. share price today?
Viatris Inc. (VTRS) last traded around $16.65 on StockPro. Prices refresh every few minutes during market hours.
What technical signals does VTRS have?
StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for VTRS. Download the app for real-time alerts.
How can I analyze Viatris Inc. stock?
Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.

Explore more on StockPro